The goal of this study is to better understand the real-world effectiveness of semaglutide use on cardio-kidney-metabolic outcomes among adults with T2D and adults with obesity (without diabetes mellitus). This is a retrospective longitudinal analysis using the LMC Diabetes Registry. The primary outcome of the study is to evaluate the change in HbA1c between baseline to 3 years of follow-up among adults with T2D who initiated semaglutide compared to adults with T2D who initiated other AHAs, including sulfonylurea, dipeptidyl peptidase-4 inhibitors, and sodium-glucose cotransporter-2 inhibitors.
A clinical diagnosis of T2D ≥ 1 year
HbA1c ≥ 6.5% (pre-index date)
Initiated semaglutide or other AHA(s) before January 1st, 2023*
Seen by an LMC endocrinologist in the last 18 months as of the query date
Clinical diagnosis of type 1 diabetes/latent autoimmune diabetes in adults (LADA)
Clinical diagnosis of T2D (obesity cohort only)
Are pregnant at the time of semaglutide or other AHA initiation or became pregnant during follow-up period
Documented history or family history of medullary thyroid carcinoma
LMC Diabetes & Endocrinology Ltd.
Lead sponsor